Is this stock the best buy in its sector following today’s update?

Should you buy this stock over two industry peers?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in Midatech (LSE: MTPH) have soared by 21% today after the international speciality pharmaceuticals company issued an upbeat trading update. Midatech expects revenue of £3.8m for the six months to 30 June, which is a rise of more than 10 times from its sales of £0.32m in the first half of the previous year. This is in line with revised market expectations for the period, which stated that Midatech was performing ahead of expectations.

During the period, Midatech has also enjoyed multiple positive advances including the launch of Zuplenz in the US to provide relief from the side effects of common cancer treatment, while its outlook for the second half of the year remains as per previous guidance.

Midatech also stated in today’s update that it’s too early to assess the long-term impact of Brexit. However, it hasn’t experienced an immediate impact following the EU referendum.

Stability and resilience

Of course, the weakening in sterling since the vote has been good news for a number of Midatech’s healthcare peers, including GlaxoSmithKline (LSE: GSK). It reports in sterling but derives a major part of its sales from abroad. As a result of this, GlaxoSmithKline’s outlook is positive, since sterling is forecast to weaken yet further against the US dollar and other major currencies.   

Clearly, GlaxoSmithKline has more appeal than just currency exchange effects. Its business model is exceptionally stable and well-diversified, with it essentially being three world-class businesses in one. Its pipeline of around 40 potential treatments is robust and should provide multiple blockbuster drugs over the medium term, while its consumer goods and vaccines businesses also have bright long term growth potential.

As such, GlaxoSmithKline has significantly greater stability and resilience than Midatech and while the smaller firm has a bright long-term growth outlook, it remains high risk. It also lacks income prospects due to it being lossmaking, while GlaxoSmithKline has a yield of 4.7% and the potential to raise dividends over the long run as its pipeline begins to deliver on its potential.

GlaxoSmithKline is also a superior income stock compared to FTSE 100 peer Hikma (LSE: HIK). The latter yields just 0.8% at the present time, but with its bottom line forecast to rise by 53% next year, dividends are expected to grow by 36% in 2017. Hikma’s growth rate puts it on a forward price-to-earnings (P/E) ratio of 18.5 and while this represents fair value for money given its strong balance sheet, long-term growth prospects and sound strategy, GlaxoSmithKline is cheaper.

It trades on a forward P/E ratio of 16.5 and when its treatment pipeline is factored-in, as well as its diverse business model, GlaxoSmithKline seems to offer the perfect mix of defensive characteristics, upward rerating potential and growth prospects. Therefore, while Hikma is a sound buy and Midatech has long-term potential, GlaxoSmithKline is the best buy of the three at the present time.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »